A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II

Here, we show model‐informed drug development (MIDD) of a novel antisense oligonucleotide, targeting PCSK9 for treatment of hypocholesteremia. The case study exemplifies use of MIDD to analyze emerging data from an ongoing first‐in‐human study, utility of the US Food and Drug Administration MIDD pil...

Full description

Saved in:
Bibliographic Details
Published in:CPT: pharmacometrics and systems pharmacology 2022-12, Vol.11 (12), p.1569-1577
Main Authors: Knöchel, Jane, Nilsson, Catarina, Carlsson, Björn, Wernevik, Linda, Hofherr, Alexis, Gennemark, Peter, Jansson‐Löfmark, Rasmus, Isaksson, Rikard, Rydén‐Bergsten, Tina, Hamrén, Bengt, Rekić, Dinko
Format: Article
Language:English
Subjects:
Case Report
Case Reports
Digitization
Drug Development
Drug dosages
Humans
Oligonucleotides, Antisense - pharmacology
Oligonucleotides, Antisense - therapeutic use
Online tutorials
Pharmaceutical Preparations
Pharmacodynamics
Prescription drugs
Proprotein Convertase 9 - genetics
Simulation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5486-b6d883ccf7e129f6fe5d156b35aaf9ede20206b08fcf4cef4d79b0db31491d443
cites cdi_FETCH-LOGICAL-c5486-b6d883ccf7e129f6fe5d156b35aaf9ede20206b08fcf4cef4d79b0db31491d443
container_end_page 1577
container_issue 12
container_start_page 1569
container_title CPT: pharmacometrics and systems pharmacology
container_volume 11
creator Knöchel, Jane
Nilsson, Catarina
Carlsson, Björn
Wernevik, Linda
Hofherr, Alexis
Gennemark, Peter
Jansson‐Löfmark, Rasmus
Isaksson, Rikard
Rydén‐Bergsten, Tina
Hamrén, Bengt
Rekić, Dinko
description Here, we show model‐informed drug development (MIDD) of a novel antisense oligonucleotide, targeting PCSK9 for treatment of hypocholesteremia. The case study exemplifies use of MIDD to analyze emerging data from an ongoing first‐in‐human study, utility of the US Food and Drug Administration MIDD pilot program to accelerate timelines, innovative use of competitor data to set biomarker targets, and use of MIDD to optimize sample size and dose selection, as well as to accelerate and de‐risk a phase IIb study. The focus of the case‐study is on the cross‐functional collaboration and other key MIDD enablers that are critical to maximize the value of MIDD, rather than the technical application of MIDD.
doi_str_mv 10.1002/psp4.12866
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_e7f981bc8d2c4134ac07a117e385317e</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_e7f981bc8d2c4134ac07a117e385317e</doaj_id><sourcerecordid>2754679313</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5486-b6d883ccf7e129f6fe5d156b35aaf9ede20206b08fcf4cef4d79b0db31491d443</originalsourceid><addsrcrecordid>eNp9ks1u1DAQgCMEotXSCw-ALHFD2sV_cWIOSNWKwopKrFQ4W4493nqVxMFOivbGiTPPyJPgbUrVXvBlrPGnb8b2FMVLglcEY_p2SANfEVoL8aQ4pUSwZc2wePpgf1KcpbTHeVUcE4mfFydMECoow6fFr3NkdII_P3-ncbIHFBzqgoU2J3zvQuzAIhunHbJwA20YOujHI6RRH3ICbddXnyXS_ehRgj4BCq3fhX4yLYTRW1ihrY4jIu_QhY9pRKPvAPkedbpHY0DDdS6ONpsXxTOn2wRnd3FRfLv48HX9aXn55eNmfX65NCWvxbIRtq6ZMa4CQqUTDkpLStGwUmsnwQLFFIsG1844bsBxW8kG24YRLonlnC2Kzey1Qe_VEH2n40EF7dVtIsSdyu363L2CysmaNKa21HDCuDa40oRUwOqSHcOieD-7hqnJz2Tyy0TdPpI-Pun9tdqFGyWrspREZsHrO0EM3ydIo9qHKfb5_opWJReVZIRl6s1MmRhSiuDuKxCsjiOgjiOgbkcgw68e9nSP_vvwDJAZ-OFbOPxHpbZXWz5L_wILu74k</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2754679313</pqid></control><display><type>article</type><title>A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II</title><source>Publicly Available Content (ProQuest)</source><source>Wiley Open Access</source><source>PubMed Central</source><source>Coronavirus Research Database</source><creator>Knöchel, Jane ; Nilsson, Catarina ; Carlsson, Björn ; Wernevik, Linda ; Hofherr, Alexis ; Gennemark, Peter ; Jansson‐Löfmark, Rasmus ; Isaksson, Rikard ; Rydén‐Bergsten, Tina ; Hamrén, Bengt ; Rekić, Dinko</creator><creatorcontrib>Knöchel, Jane ; Nilsson, Catarina ; Carlsson, Björn ; Wernevik, Linda ; Hofherr, Alexis ; Gennemark, Peter ; Jansson‐Löfmark, Rasmus ; Isaksson, Rikard ; Rydén‐Bergsten, Tina ; Hamrén, Bengt ; Rekić, Dinko</creatorcontrib><description>Here, we show model‐informed drug development (MIDD) of a novel antisense oligonucleotide, targeting PCSK9 for treatment of hypocholesteremia. The case study exemplifies use of MIDD to analyze emerging data from an ongoing first‐in‐human study, utility of the US Food and Drug Administration MIDD pilot program to accelerate timelines, innovative use of competitor data to set biomarker targets, and use of MIDD to optimize sample size and dose selection, as well as to accelerate and de‐risk a phase IIb study. The focus of the case‐study is on the cross‐functional collaboration and other key MIDD enablers that are critical to maximize the value of MIDD, rather than the technical application of MIDD.</description><identifier>ISSN: 2163-8306</identifier><identifier>EISSN: 2163-8306</identifier><identifier>DOI: 10.1002/psp4.12866</identifier><identifier>PMID: 36126230</identifier><language>eng</language><publisher>United States: John Wiley &amp; Sons, Inc</publisher><subject>Case Report ; Case Reports ; Digitization ; Drug Development ; Drug dosages ; Humans ; Oligonucleotides, Antisense - pharmacology ; Oligonucleotides, Antisense - therapeutic use ; Online tutorials ; Pharmaceutical Preparations ; Pharmacodynamics ; Prescription drugs ; Proprotein Convertase 9 - genetics ; Simulation</subject><ispartof>CPT: pharmacometrics and systems pharmacology, 2022-12, Vol.11 (12), p.1569-1577</ispartof><rights>2022 AstraZeneca. published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</rights><rights>2022 AstraZeneca. CPT: Pharmacometrics &amp; Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</rights><rights>2022. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5486-b6d883ccf7e129f6fe5d156b35aaf9ede20206b08fcf4cef4d79b0db31491d443</citedby><cites>FETCH-LOGICAL-c5486-b6d883ccf7e129f6fe5d156b35aaf9ede20206b08fcf4cef4d79b0db31491d443</cites><orcidid>0000-0001-9839-2433 ; 0000-0002-5310-8002</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2754679313?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2754679313?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,11542,25732,27903,27904,36991,38495,43874,44569,46031,46455,53770,53772,74159,74873</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36126230$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Knöchel, Jane</creatorcontrib><creatorcontrib>Nilsson, Catarina</creatorcontrib><creatorcontrib>Carlsson, Björn</creatorcontrib><creatorcontrib>Wernevik, Linda</creatorcontrib><creatorcontrib>Hofherr, Alexis</creatorcontrib><creatorcontrib>Gennemark, Peter</creatorcontrib><creatorcontrib>Jansson‐Löfmark, Rasmus</creatorcontrib><creatorcontrib>Isaksson, Rikard</creatorcontrib><creatorcontrib>Rydén‐Bergsten, Tina</creatorcontrib><creatorcontrib>Hamrén, Bengt</creatorcontrib><creatorcontrib>Rekić, Dinko</creatorcontrib><title>A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II</title><title>CPT: pharmacometrics and systems pharmacology</title><addtitle>CPT Pharmacometrics Syst Pharmacol</addtitle><description>Here, we show model‐informed drug development (MIDD) of a novel antisense oligonucleotide, targeting PCSK9 for treatment of hypocholesteremia. The case study exemplifies use of MIDD to analyze emerging data from an ongoing first‐in‐human study, utility of the US Food and Drug Administration MIDD pilot program to accelerate timelines, innovative use of competitor data to set biomarker targets, and use of MIDD to optimize sample size and dose selection, as well as to accelerate and de‐risk a phase IIb study. The focus of the case‐study is on the cross‐functional collaboration and other key MIDD enablers that are critical to maximize the value of MIDD, rather than the technical application of MIDD.</description><subject>Case Report</subject><subject>Case Reports</subject><subject>Digitization</subject><subject>Drug Development</subject><subject>Drug dosages</subject><subject>Humans</subject><subject>Oligonucleotides, Antisense - pharmacology</subject><subject>Oligonucleotides, Antisense - therapeutic use</subject><subject>Online tutorials</subject><subject>Pharmaceutical Preparations</subject><subject>Pharmacodynamics</subject><subject>Prescription drugs</subject><subject>Proprotein Convertase 9 - genetics</subject><subject>Simulation</subject><issn>2163-8306</issn><issn>2163-8306</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9ks1u1DAQgCMEotXSCw-ALHFD2sV_cWIOSNWKwopKrFQ4W4493nqVxMFOivbGiTPPyJPgbUrVXvBlrPGnb8b2FMVLglcEY_p2SANfEVoL8aQ4pUSwZc2wePpgf1KcpbTHeVUcE4mfFydMECoow6fFr3NkdII_P3-ncbIHFBzqgoU2J3zvQuzAIhunHbJwA20YOujHI6RRH3ICbddXnyXS_ehRgj4BCq3fhX4yLYTRW1ihrY4jIu_QhY9pRKPvAPkedbpHY0DDdS6ONpsXxTOn2wRnd3FRfLv48HX9aXn55eNmfX65NCWvxbIRtq6ZMa4CQqUTDkpLStGwUmsnwQLFFIsG1844bsBxW8kG24YRLonlnC2Kzey1Qe_VEH2n40EF7dVtIsSdyu363L2CysmaNKa21HDCuDa40oRUwOqSHcOieD-7hqnJz2Tyy0TdPpI-Pun9tdqFGyWrspREZsHrO0EM3ydIo9qHKfb5_opWJReVZIRl6s1MmRhSiuDuKxCsjiOgjiOgbkcgw68e9nSP_vvwDJAZ-OFbOPxHpbZXWz5L_wILu74k</recordid><startdate>202212</startdate><enddate>202212</enddate><creator>Knöchel, Jane</creator><creator>Nilsson, Catarina</creator><creator>Carlsson, Björn</creator><creator>Wernevik, Linda</creator><creator>Hofherr, Alexis</creator><creator>Gennemark, Peter</creator><creator>Jansson‐Löfmark, Rasmus</creator><creator>Isaksson, Rikard</creator><creator>Rydén‐Bergsten, Tina</creator><creator>Hamrén, Bengt</creator><creator>Rekić, Dinko</creator><general>John Wiley &amp; Sons, Inc</general><general>John Wiley and Sons Inc</general><general>Wiley</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-9839-2433</orcidid><orcidid>https://orcid.org/0000-0002-5310-8002</orcidid></search><sort><creationdate>202212</creationdate><title>A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II</title><author>Knöchel, Jane ; Nilsson, Catarina ; Carlsson, Björn ; Wernevik, Linda ; Hofherr, Alexis ; Gennemark, Peter ; Jansson‐Löfmark, Rasmus ; Isaksson, Rikard ; Rydén‐Bergsten, Tina ; Hamrén, Bengt ; Rekić, Dinko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5486-b6d883ccf7e129f6fe5d156b35aaf9ede20206b08fcf4cef4d79b0db31491d443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Case Report</topic><topic>Case Reports</topic><topic>Digitization</topic><topic>Drug Development</topic><topic>Drug dosages</topic><topic>Humans</topic><topic>Oligonucleotides, Antisense - pharmacology</topic><topic>Oligonucleotides, Antisense - therapeutic use</topic><topic>Online tutorials</topic><topic>Pharmaceutical Preparations</topic><topic>Pharmacodynamics</topic><topic>Prescription drugs</topic><topic>Proprotein Convertase 9 - genetics</topic><topic>Simulation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Knöchel, Jane</creatorcontrib><creatorcontrib>Nilsson, Catarina</creatorcontrib><creatorcontrib>Carlsson, Björn</creatorcontrib><creatorcontrib>Wernevik, Linda</creatorcontrib><creatorcontrib>Hofherr, Alexis</creatorcontrib><creatorcontrib>Gennemark, Peter</creatorcontrib><creatorcontrib>Jansson‐Löfmark, Rasmus</creatorcontrib><creatorcontrib>Isaksson, Rikard</creatorcontrib><creatorcontrib>Rydén‐Bergsten, Tina</creatorcontrib><creatorcontrib>Hamrén, Bengt</creatorcontrib><creatorcontrib>Rekić, Dinko</creatorcontrib><collection>Wiley Open Access</collection><collection>Wiley Free Archive</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>CPT: pharmacometrics and systems pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Knöchel, Jane</au><au>Nilsson, Catarina</au><au>Carlsson, Björn</au><au>Wernevik, Linda</au><au>Hofherr, Alexis</au><au>Gennemark, Peter</au><au>Jansson‐Löfmark, Rasmus</au><au>Isaksson, Rikard</au><au>Rydén‐Bergsten, Tina</au><au>Hamrén, Bengt</au><au>Rekić, Dinko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II</atitle><jtitle>CPT: pharmacometrics and systems pharmacology</jtitle><addtitle>CPT Pharmacometrics Syst Pharmacol</addtitle><date>2022-12</date><risdate>2022</risdate><volume>11</volume><issue>12</issue><spage>1569</spage><epage>1577</epage><pages>1569-1577</pages><issn>2163-8306</issn><eissn>2163-8306</eissn><abstract>Here, we show model‐informed drug development (MIDD) of a novel antisense oligonucleotide, targeting PCSK9 for treatment of hypocholesteremia. The case study exemplifies use of MIDD to analyze emerging data from an ongoing first‐in‐human study, utility of the US Food and Drug Administration MIDD pilot program to accelerate timelines, innovative use of competitor data to set biomarker targets, and use of MIDD to optimize sample size and dose selection, as well as to accelerate and de‐risk a phase IIb study. The focus of the case‐study is on the cross‐functional collaboration and other key MIDD enablers that are critical to maximize the value of MIDD, rather than the technical application of MIDD.</abstract><cop>United States</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>36126230</pmid><doi>10.1002/psp4.12866</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-9839-2433</orcidid><orcidid>https://orcid.org/0000-0002-5310-8002</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2163-8306
ispartof CPT: pharmacometrics and systems pharmacology, 2022-12, Vol.11 (12), p.1569-1577
issn 2163-8306
2163-8306
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_e7f981bc8d2c4134ac07a117e385317e
source Publicly Available Content (ProQuest); Wiley Open Access; PubMed Central; Coronavirus Research Database
subjects Case Report
Case Reports
Digitization
Drug Development
Drug dosages
Humans
Oligonucleotides, Antisense - pharmacology
Oligonucleotides, Antisense - therapeutic use
Online tutorials
Pharmaceutical Preparations
Pharmacodynamics
Prescription drugs
Proprotein Convertase 9 - genetics
Simulation
title A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T20%3A37%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20case%E2%80%90study%20of%20model%E2%80%90informed%20drug%20development%20of%20a%20novel%20PCSK9%20anti%20sense%20oligonucleotide.%20Part%201:%20First%20time%20in%20man%20to%20phase%20II&rft.jtitle=CPT:%20pharmacometrics%20and%20systems%20pharmacology&rft.au=Kn%C3%B6chel,%20Jane&rft.date=2022-12&rft.volume=11&rft.issue=12&rft.spage=1569&rft.epage=1577&rft.pages=1569-1577&rft.issn=2163-8306&rft.eissn=2163-8306&rft_id=info:doi/10.1002/psp4.12866&rft_dat=%3Cproquest_doaj_%3E2754679313%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5486-b6d883ccf7e129f6fe5d156b35aaf9ede20206b08fcf4cef4d79b0db31491d443%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2754679313&rft_id=info:pmid/36126230&rfr_iscdi=true